RxDoctor Payments DataLook up a doctor →

Marshall Anderson, MD

Internal Medicine · Burlington, NCNPI 1194766378

Payments from drug & device makers

$442,111in general payments, 2019–2025

Across 966 payments — averaging $457.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$286K
  • Esperion Therapeutics, Inc.$156K
  • Novo Nordisk$32

What the payments were for

  • Education$32100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS732$286,482
Esperion Therapeutics, Inc.233$155,596
Novo Nordisk1$32

How this compares

$442,111 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$216,249
Medicare patients
359
Services billed
5,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin464$505,497
EliquisApixaban491$280,280
RybelsusSemaglutide108$191,489
OzempicSemaglutide158$176,279
TrulicityDulaglutide121$138,558
MounjaroTirzepatide99$118,988
XareltoRivaroxaban100$58,164
MyrbetriqMirabegron57$27,438
JanuviaSitagliptin Phosphate35$26,507
FarxigaDapagliflozin Propanediol22$25,464
WegovySemaglutide12$21,432
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$20,464
AbrysvoRsv Vacc, Pref A And Pref B/Pf48$15,884
LinzessLinaclotide23$14,441
LatudaLurasidone Hcl11$13,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic, Wegovy$32$389,200278 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Burlington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →